Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Predicted Market Size Trajectory For The Patient Derived Xenograft (PDX) Models Market From 2025 To 2034?
The patient derived xenograft (pdx) models market has shown substantial growth in recent times. It is anticipated to expand from $0.4 billion in 2024 to $0.47 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.5%. This past growth is largely driven by investments in research and development, supportive regulatory policies, strategic partnerships and collaborations, a growing number of contract research organizations (CROs), and an increasing prevalence of cancer.
The patient derived xenograft (pdx) models market size is projected to experience substantial expansion over the coming years. This market is set to reach $0.81 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.9%. Several factors are driving this anticipated growth during the forecast period, including the increasing demand for personalized medicine, a rising need for humanized PDX models, the escalating incidence of cancer, an intensified focus on precision oncology, and greater R&D investment in cancer research. Key trends expected in the forecast period encompass technological advancements, continued high demand for humanized PDX models, expanding collaborative research efforts, increasing financial commitments to cancer research, and a heightened emphasis on immuno-oncology.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17226&type=smp
Which Drivers Are Shaping The Patient Derived Xenograft (PDX) Models Industry’s Market Share?
The rising demand for personalized medicine is anticipated to fuel the expansion of the patient-derived xenograft (PDX) models market in the future. Personalized medicine focuses on customizing medical treatments for each patient’s unique characteristics, taking into account factors like genetics, environment, and lifestyle. This increasing demand for personalized medicine is driven by advancements in genomic research, which allow for tailored treatments based on individual genetic profiles, leading to more effective and targeted healthcare outcomes. Patient-derived xenograft (PDX) models assist personalized medicine by enabling the testing of tumors from individual patients to predict treatment responses and subsequently customize therapies. For example, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit umbrella organization, indicated that in 2023, the FDA approved 16 new personalized treatments for rare diseases, marking a notable increase from six approvals in 2022. Thus, the demand for personalized medicine is a key driver for the growth of the patient-derived xenograft (PDX) models market.
What Are The Primary Types Of Segments Analyzed In The Patient Derived Xenograft (PDX) Models Market?
The patient derived xenograft (pdx) modelsmarket covered in this report is segmented –
1) By Type: Mice Models; Rat Models
2) By Technique: Heterotopic Implantation; Orthotropic Implantation
3) By Tumor Type: Gastrointestinal Tumor Models; Lung Tumor Models; Hematological Tumor Models; Gynecological Tumor Models; Respiratory Tumor Models; Urological Tumor Models; Other Tumor Models
4) By Application: Preclinical Drug Development; Precision Medicine; Co-Clinical Trials; Basic Cancer Research
5) By End-User: Academic And Research Organizations; Contract Research Organizations; Pharmaceutical And Biotechnological Companies; Other End-Users
Subsegments:
1) By Mice Models: Immunodeficient Mice Models (Nude Mice, SCID Mice); Humanized Mice Models; Genetically Modified Mice Models
2) By Rat Models: Immunodeficient Rat Models; Humanized Rat Models; Genetically Modified Rat Models
What Long-Term Trends Will Shape The Future Growth Of The Patient Derived Xenograft (PDX) Models Industry?
Key players in the patient-derived xenograft (PDX) models market are advancing innovative models featuring in vivo bioluminescence imaging, which allows for real-time tracking of tumor progression. This imaging technology aids PDX models by facilitating non-invasive, real-time surveillance of tumor metastasis and responses to therapy, thereby boosting the efficacy of preclinical drug development research. As an illustration, in March 2024, InVitro Research Solutions Private Limited, an India-based Contract Research Organization (CRO), introduced an advanced orthotopic model of human glioblastoma in NSG-SGM3 mice, leveraging patient-derived xenografts (PDX) and in vivo bioluminescence imaging. The objective of this model is to facilitate personalized treatment for glioblastoma, recognized as the most prevalent and aggressive form of brain cancer. Such models hold crucial importance for comprehending glioblastoma biology and for assessing novel targeted therapies and immunotherapies to enhance patient outcomes.
Which Industry Leaders Are Driving Innovation Across The Patient Derived Xenograft (PDX) Models Market?
Major companies operating in the patient derived xenograft (PDX) models market are Laboratory Corporation of America Holdings, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., The Jackson Laboratory, Inotiv Inc, Biocytogen Pharmaceuticals Co. Ltd., Taconic Biosciences Inc, BioDuro-Sundia Inc, Horizon Discovery Ltd., Crown Bioscience Inc., Champions Oncology Inc., Oncodesign Services S.A, Genesis Biotechnology Group LLC., Creative Animodel, Abnova Corp., Certis Oncology Solutions Inc., Xentech, Aragen Bioscience Inc., EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH., Urosphere, Hera BioLabs, InnoSer, Pharmatest Services Ltd., IVRS AB, Altogen Inc
Download The Full Report For Exclusive Market Findings:
Which Region Shows The Highest Potential For Future Expansion In The Patient Derived Xenograft (PDX) Models Market?
North America was the largest region in the patient derived xenograft (PDX) models market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (PDX) models market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Patient Derived Xenograft (PDX) Models Market Report:
https://www.thebusinessresearchcompany.com/customise?id=17226&type=smp
Browse Through More Reports Similar to the Global Patient Derived Xenograft (PDX) Models Market 2025, By The Business Research Company
Patient Simulators Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/patient-simulators-global-market-report
Patient Portal Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/patient-portal-global-market-report
Patient Safety And Risk Management Software Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model